← Back to Clinical Trials
Recruiting NCT05498675

NCT05498675 Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05498675
Status Recruiting
Phase
Sponsor Beijing Friendship Hospital
Condition Sacubitril/Valsartan
Study Type OBSERVATIONAL
Enrollment 180 participants
Start Date 2021-09-01
Primary Completion 2026-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 70 Years
Study Type OBSERVATIONAL
Interventions
Sacubitril / Valsartan Oral Tablet [Entresto]ACEI/ARB

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 180 participants in total. It began in 2021-09-01 with a primary completion date of 2026-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this study is to investigate the effect of sacubitril/valsartan on cardiac function assessed by cardiac magnetic resonance (CMR) in hypertensive patients stratified by BMI.

Eligibility Criteria

Inclusion Criteria: * Patients with essential hypertension * 18-70 years old * No major barriers to provide written consent Exclusion Criteria: * Secondary hypertension, except because of sleep apnea * cardiovascular disease (myocardial infarction, heart failure, stroke or coronary revascularization) within 6 months * Severe concomitant diseases (autoimmune disease, malignancy, late stage of liver diseases, respiratory diseases and digestive diseases) * Unable to understand or comply with the study procedures

Contact & Investigator

Central Contact

Rongchong Huang, M.D.

✉ rchuang@ccmu.edu.cn

📞 +86-13811039417

Principal Investigator

Rongchong Huang, M.D.

PRINCIPAL INVESTIGATOR

Beijing Friendship Hospital

Frequently Asked Questions

Who can join the NCT05498675 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Sacubitril/Valsartan. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05498675 currently recruiting?

Yes, NCT05498675 is actively recruiting participants. Contact the research team at rchuang@ccmu.edu.cn for enrollment information.

Where is the NCT05498675 trial being conducted?

This trial is being conducted at Beijing, China.

Who is sponsoring the NCT05498675 clinical trial?

NCT05498675 is sponsored by Beijing Friendship Hospital. The principal investigator is Rongchong Huang, M.D. at Beijing Friendship Hospital. The trial plans to enroll 180 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology